Track 01 of 9
GLP-1 & Incretin Therapies
Semaglutide, tirzepatide and next-generation weight-loss medications.
Incretin-based pharmacotherapy has redefined obesity medicine, with semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) now delivering 15–22% mean weight loss in the STEP and SURMOUNT programs. GSOD 2027 will present long-term data including SELECT cardiovascular outcomes, SUMMIT in HFpEF-obesity, FLOW in diabetic kidney disease, and the MASH readouts that are reshaping hepatology. Sessions will also examine the next wave: retatrutide (GGG triple agonist), oral orforglipron, survodutide, CagriSema, mazdutide, and OASIS oral semaglutide — alongside supply, compounding exit, and Medicare coverage debates.
Focus areas
- SELECT, SURMOUNT-MMO and cardiovascular outcomes of GLP-1 RAs
- Triple agonists: retatrutide GGG and survodutide phase 3 readouts
- Oral incretins: orforglipron, OASIS oral semaglutide, danuglipron
- CagriSema, mazdutide and amylin/glucagon co-agonism
- SUMMIT HFpEF, FLOW kidney and ESSENCE MASH indication expansion
- Weight regain on discontinuation and maintenance dosing strategies
- Medicare coverage, compounded shortage exit and global access